A Montréal company is first out of the gate with a new blood test that can rapidly identify people who are pre-diabetic, allowing for more accurate tracking of disease progression and treatment monitoring. With mentoring and funding support from the Quebec Consortium for Drug Delivery, Caprion Proteomics identified biomarkers – the protein fingerprints in cells – that measure mass and function of pancreatic cells in diabetes. Diagnosing people at the pre-diabetes stage is critical for arresting or even preventing the progression of this debilitating disease, with significant savings to the health care system. Caprion has established a new diagnostic division to commercialize the technology.